← All trials
NCT05892653
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2023
- Primary completion
- May 29, 2028
- Completion date
- May 29, 2028
- First posted
- Jun 7, 2023
- Last posted
- Jul 24, 2023
- Enrollment
- 52
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ABM Therapeutics, Inc.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.